Martínez Chamorro, E. J., D'Albuquerque, P. M., Pérez Catalán, I., Pich, J., & Gatell, J. M. (2012). Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir.
Citação norma ChicagoMartínez Chamorro, Esteban José, Polyana M. D'Albuquerque, Ignacio Pérez Catalán, Judit Pich, e José M. Gatell. Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir. 2012.
Citação norma MLAMartínez Chamorro, Esteban José, et al. Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir. 2012.